Please assess the completion status of the following clinical trial:

Trial Title: Daratumumab in Treatment of PGNMID and C3 GN

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age~* Renal biopsy read at Mayo Clinic confirming the diagnosis of PGNMID or C3 GN~* In cases of C3GN serum electrophoresis with immunofixation should confirm presence of monoclonal gammopathy~* Proteinuria ≥ 1000 mg over 24 hours~* eGFR ≥ 20 mL/min/SA~* Subjects able and willing to give informed consent~Exclusion Criteria:~* Pregnancy~* Hepatitis B or C, HIV~* Multiple myeloma~* Anemia with Hgb \< 8.5 g/dL~* Thrombocytopenia with platelet count \< 100,000~* Leukopenia with WBC \< 3.5~* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication~* Unable to provide consent~* Patients receiving therapy with oral prednisone or glucocorticoid equivalent in the last 6 weeks~* Patients who had received immunosuppressive therapy including cyclophosphamide, MMF, cyclosporine, tacrolimus or azathioprine in the last 3 months~* Patients who received rituximab previously with CD20 count of zero at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab (Type: EXPERIMENTAL): Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses

Based on this trial design, predict the completion outcome and termination type (if applicable).